An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics : CCRLORUSSO, Patricia M; BOERNER, Scott A; SEYMOUR, Lesley et al.Clinical cancer research (Print). 2010, Vol 16, Num 6, pp 1710-1718, issn 1078-0432, 9 p.Article

Validation and implementation of a liquid chromatography/tandem mass spectrometry assay for quantitation of the total and unbound R04929097, a γ-secretase inhibitor targeting Notch signaling, in human plasmaJIANMEI WU; WIEGAND, Richard; LORUSSO, Patricia et al.Journal of chromatography. B. 2011, Vol 879, Num 19, pp 1537-1543, issn 1570-0232, 7 p.Article

Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogsOGITA, Shin; LORUSSO, Patricia.Targeted oncology. 2011, Vol 6, Num 2, pp 103-117, issn 1776-2596, 15 p.Article

Phase I studies of ZD1839 in patients with common solid tumorsLORUSSO, Patricia M.Seminars in oncology. 2003, Vol 30, Num 1, pp 21-29, issn 0093-7754, 9 p., SUP1Article

The Intersection of Immune-Directed and Molecularly Targeted Therapy in Advanced Melanoma: Where We Have Been, Are, and Will BeSULLIVAN, Ryan J; LORUSSO, Patricia M; FLAHERTY, Keith T et al.Clinical cancer research (Print). 2013, Vol 19, Num 19, pp 5283-5291, issn 1078-0432, 9 p.Article

Implications of Plasma Protein Binding for Pharmacokinetics and Pharmacodynamics of the γ-Secretase Inhibitor RO4929097JIANMEI WU; LORUSSO, Patricia M; MATHERLY, Larry H et al.Clinical cancer research (Print). 2012, Vol 18, Num 7, pp 2066-2079, issn 1078-0432, 14 p.Article

Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometryWIEGAND, Richard; JIANMEI WU; XIANYI SHA et al.Journal of chromatography. B. 2010, Vol 878, Num 3-4, pp 333-339, issn 1570-0232, 7 p.Article

Results of a phase 1, randomized study evaluating the effects of food and diurnal variation on the pharmacokinetics of linifanibHAO XIONG; CHIU, Yi-Lin; RICKER, Justin L et al.Cancer chemotherapy and pharmacology. 2014, Vol 74, Num 1, pp 55-61, issn 0344-5704, 7 p.Article

Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumorsANNUNZIATA, Christina M; KOHN, Elise C; LORUSSO, Patricia et al.Investigational new drugs. 2013, Vol 31, Num 1, pp 77-84, issn 0167-6997, 8 p.Article

A phase II study of bortezomib in the treatment of metastatic malignant melanomaMARKOVIC, Svetomir N; GEYER, Susan M; ERLICHMAN, Charles et al.Cancer. 2005, Vol 103, Num 12, pp 2584-2589, issn 0008-543X, 6 p.Article

Factors associated with breast Cancer clinical trials participation and enrollment at a large academic medical centerSIMON, Michael S; WEI DU; FLAHERTY, Lawrence et al.Journal of clinical oncology. 2004, Vol 22, Num 11, pp 2046-2052, issn 0732-183X, 7 p.Article

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: Histopathologic and molecular consequences of receptor inhibitionALBANELL, Joan; ROJO, Federico; NICHOLSON, Robert I et al.Journal of clinical oncology. 2002, Vol 20, Num 1, pp 110-124, issn 0732-183XArticle

Predictive Value of Phase I Trials for Safety in Later Trials and Final Approved Dose: Analysis of 61 Approved Cancer DrugsJARDIM, Denis L; HESS, Kenneth R; LORUSSO, Patricia et al.Clinical cancer research (Print). 2014, Vol 20, Num 2, pp 281-288, issn 1078-0432, 8 p.Article

Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528GADGEEL, Shirish M; LEW, Danika L; SYNOLD, Timothy W et al.Cancer chemotherapy and pharmacology. 2013, Vol 72, Num 5, pp 1089-1096, issn 0344-5704, 8 p.Article

Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family TumorsNAING, Aung; LORUSSO, Patricia; SIQING FU et al.Clinical cancer research (Print). 2012, Vol 18, Num 9, pp 2625-2631, issn 1078-0432, 7 p.Article

Phase I study of bryostatin 1 and gemcitabineEL-RAYES, Basil F; GADGEEL, Shirish; SHIELDS, Anthony F et al.Clinical cancer research. 2006, Vol 12, Num 23, pp 7059-7062, issn 1078-0432, 4 p.Article

Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients With Advanced Solid TumorsKROP, Ian; DEMUTH, Tim; BLACKMAN, Samuel et al.Journal of clinical oncology. 2012, Vol 30, Num 19, pp 2307-2313, issn 0732-183X, 7 p.Article

Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2-Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid TumorsMITA, Alain C; TAKIMOTO, Chris H; ZHONG, Z. Don et al.Clinical cancer research (Print). 2010, Vol 16, Num 11, pp 3044-3056, issn 1078-0432, 13 p.Article

Phase II Study of Predictive Biomarker Profiles for Response Targeting Human Epidermal Growth Factor Receptor 2 (HER-2) in Advanced Inflammatory Breast Cancer With Lapatinib MonotherapyJOHNSTON, Stephen; TRUDEAU, Maureen; HARRIS, Jennifer et al.Journal of clinical oncology. 2008, Vol 26, Num 7, pp 1066-1072, issn 0732-183X, 7 p.Article

Preclinical efficacy evaluations of XK-469: Dose schedule, route and cross-resistance behavior in tumor bearing micePOLIN, Lisa; WHITE, Kathryn; HORWITZ, Jerome P et al.Investigational new drugs. 2002, Vol 20, Num 1, pp 13-22, issn 0167-6997, 10 p.Article

Analysis of skeletal-related events in breast cancer and response to therapyLORUSSO, Patricia.Seminars in oncology. 2001, Vol 28, Num 4, pp 22-27, issn 0093-7754, SUP11Conference Paper

Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2LORUSSO, Patricia; VENKATAKRISHNAN, Karthik; CHIOREAN, E. Gabriela et al.Investigational new drugs. 2014, Vol 32, Num 1, pp 160-170, issn 0167-6997, 11 p.Article

Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid TumorsSESSA, Cristiana; LORUSSO, Patricia; VEYRAT-FOLLET, Christine et al.Clinical cancer research (Print). 2013, Vol 19, Num 17, pp 4832-4842, issn 1078-0432, 11 p.Article

Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group StudySHIBATA, Stephen I; CHUNG, Vincent; O'NEIL, Bert H et al.Clinical cancer research (Print). 2013, Vol 19, Num 13, pp 3631-3639, issn 1078-0432, 9 p.Article

Pharmacokinetic and Pharmacodynamic Analysis of Circulating Biomarkers of Anti-NRP1, a Novel Antiangiogenesis Agent, in Two Phase I Trials in Patients with Advanced Solid TumorsYAN XIN; LI, Jessica; WATTS, Ryan et al.Clinical cancer research (Print). 2012, Vol 18, Num 21, pp 6040-6048, issn 1078-0432, 9 p.Article